Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) --...

Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...

Celsion Corporation Issues Letter to Stockholders Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study, and Phase III OPTIMA Study Conclusions LAWRENCEVILLE, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...

Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,...

Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB)...